SkyePharma submits Flutiform NDA

SkyePharma (LSE:SKP) submitted an NDA to FDA for Flutiform fluticasone/formoterol for maintenance treatment of asthma in patients age 12 and older. Abbott (NYSE:ABT) has U.S. rights to the fixed-dose ...